Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus

NCT04519073 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Bronchiolitis Due to Respiratory Syncytial Virus

Interventions

BIOLOGICAL: V-306 candidate vaccine

Sponsor

Virometix

Collaborators

[object Object]
[object Object]